Kyowa Kirin Co., Ltd.
基本情報
- 所在地
- 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004
- 社長
- Abdul Mullick
- 資本金
- 26,745 円
- 従業員数(単独)
- 従業員数(連結)
- 開始日
- 終了日
サイト
事業内容
関連会社
| 会社名 | Group | 親会社 | 子会社 | 得意先 | 仕入先 | 業務提携 | 銀行等 | 株主等 |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
| CRT Japan | ||||||||
| Caux Round Table Japan | ||||||||
| International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) | ||||||||
| Japan Center for Engagement and Remedy on Business and Human Rights (JaCER) | ||||||||
| Kyowa Kirin USA Holdings, Inc. |
関連図
沿革
Establishment of Kyowa Hakko Kogyo Co., Ltd. as a secondary company of Kyowa Sangyo Co., Ltd, as part of industrial readjustment plans.![]()
Introduced production technology of Streptomycin, an anti-tubercular drug, from US pharmaceutical company Merck & Co., Inc. and succeeded in its mass production. Contributed to the wiping out of tuberculosis in Japan (beginning of involvement in pharmaceutical business operations).![]()
Success of isolation and commercially mass-production of the anticancer drug, Mitomycin C. Invention of the process of L-glutamic acid production by fermentation (a world first).![]()
Initiation of full-scale involvement in the pharmaceutical business. Release of Mitomycin C, an anticancer drug, and Spiramycin, an antibiotic drug.![]()
The Research Institute for Production Development foundation begins full-scale research towards the commercialization of erythropoietin.![]()
Supported the establishment in the U.S.A. of the La Jolla Institute for Allergy and Immunology (LIAI).![]()
Establishment of BioWa, Inc. in the United States to promote Kyowa Hakko's therapeutic antibody business.![]()
The launch of Kirin Pharma Company, Limited to accompany the adoption by Kirin Brewery Company, Limited of a pure holding company system. Release of NESP®, a long-acting erythropoietic stimulating drug. Established COMPLEGENT®, a novel antibody engineering technology that enhances the efficacy of antibodies, and licensed to BioWa, Inc, its subsidiary. Capital alliance between Kyowa Hakko Group and Kirin Group.![]()
Release of REGPARA®, a drug for secondary hyperparathyroidism. Spun off its biochemical business, establishing Kyowa Hakko Bio Co., Ltd. Kyowa Hakko Kirin was formed through the merger of Kyowa Hakko Kogyo and Kirin Pharma.![]()
ProStrakan Completes Acquisition of Archimedes. Launch of Sustained-Duration G-CSF Product G-LASTA® in Japan.![]()
Rebranding Western Pharmaceutical Subsidiaries to 'Kyowa Kirin'. Launch of LUMICEF® for Psoriasis Treatment in Japan.![]()
Crysvita® approved in the US and Europe, sales to start as a treatment for patients with X-linked hypophosphatemia. Poteligeo® approved in the US and Europe as a treatment for mycosis fungoides (MF) and Sézary syndrome (SS).![]()
Crysvita® launched in Japan for the treatment of FGF23-related Hypophosphatemic Rickets and Osteomalacia.![]()
Poteligeo® launched in Europe for the treatment for mycosis fungoides (MF) and Sézary syndrome (SS).![]()
Agreement reached with Amgen to jointly develop and commercialize KHK4083, a Kyowa Kirin-discovered anti-OX40 fully human monoclonal antibody.![]()
Declared support for the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD).![]()
An automated injection device "G-Lasta® Subcutaneous Injection 3.6 mg BodyPod" launched in Japan for the long-acting G-CSF preparation, G-Lasta®.![]()
Q-TOWER, the new biopharmaceutical analysis facility completed at Takasaki Plant, Kyowa Kirin's major biopharmaceutical manufacturing site.![]()
PHOZEVEL® approved in Japan for the treatment of Hyperphosphatemia in chronic kidney disease patients.![]()
Kyowa Kirin announced the acquisition of UK company Orchard Therapeutics with strength in hematopoietic stem cell gene therapy.![]()
Lenmeldy™ , an innovative hematopoietic stem cell (HSC) gene therapy, approved and launched in the United States.![]()
A global strategic collaboration signed to develop and commercialize menin inhibitor ziftomenib in acute leukemias with Kura Oncology.![]()
ニュース
ニュースはありません。